Contract Pharmacal Corp. (CPC) is a full-service contract research organization serving pharmaceutical companies, retailers, and wholesalers worldwide. CPC manufactures dietary supplements, a variety of over-the-counter medications, and private label and generic prescription drugs. The company's prescription portfolio consists of mostly of prenatal and multi-vitamins, as well as urinary tract infection treatments. Production capabilities also include manufacturing tablets, gelatin capsules, softgels, and liquids that can be packaged in bottles, cans, blister pouches, and cartons. CPC (in business since 1971) is owned and operated by CEO Matt Wolf and the founding Wolf family.

Alfacell Corporation was founded in 1981 and is headquartered in Somerset, New Jersey. Alfacell Corporation, a biopharmaceutical company, primarily engages in the discovery and development of a class of therapeutic drugs for the treatment of cancer and other pathological conditions. Its proprietary drug discovery and development program consists of therapeutics developed from amphibian ribonucleases. The company's lead drug product candidate, ONCONASE is evaluated in human clinical trials for the treatment of various forms of cancer. It also focuses on new drug application for unresectable malignant mesothelioma. In addition, the company completed a Phase I clinical trial for the treatment of non-small cell lung cancer.

CEL-SCI Corporation was founded in 1983 and is based in Vienna, Virginia. CEL-SCI Corporation, is engaged in the development of a product called Multikine for the treatment of cancer. It simulates the activities of a healthy person's immune system, which battles cancer every day. Multikine is multi-targeted, it is the cancer immunotherapy that both kills cancer cells in a targeted fashion and activates the general immune system to destroy the cancer. Multikine is a type of immunotherapy in that it is immunotherapy, incorporating both active and passive immune activity.

Otsuka Pharmaceutical Co. (OPC) is a manufacturer and distributor of pharmaceuticals, clinical testing and medical equipment, and food products. The company operates six business segments specializing in branded prescriptions, over-the-counter drugs, clinical nutritionals, diagnostic substances and devices, nutraceuticals, and skin care products ("cosmedics"). OPC's medicinal products include Mikelan eye drops for glaucoma treatment and Pletaal anti-platelet treatment. The company's line of nutraceutical consumer health products include FIBE-MINI dietary fiber supplement, Calorie Mate foods, and Pocari Sweat sports drink. Otsuka Pharmaceutical is part of the very diverse Otsuka Group.

Tongjitang Chinese Medicines Company was founded in 1995 and is headquartered in Shenzhen, the People's Republic of China. Tongjitang Chinese Medicines Company, through its subsidiaries, engages in the development, manufacture, marketing, and sale of Chinese medicines, nutritional products, and Tibetan recipe-originated plant-based medicines in the People’s Republic of China. The company also involves in the wholesale and retail of medicines. It offers Xianling Gubao for the treatment of osteoporosis, osteoarthritis, ischemic bone necrosis, and bone fractures; Zaoren Anshen Capsules for the treatment of insomnia; and moisturizing and anti-itching Capsules for the treatment of inflammatory skin conditions. The company also produces and sells Dianbaizhu Syrup for the treatment of vertigo; Compound Glycyrrhiza oral solution for the treatment of upper respiratory infections; Jiao Ti Guo Jiao Bi Capsules that prevent gastritis and ulcers; Bu Shen Yi Lao capsules, which improve memory, breathing, hearing, and general malaise; Xin Nao Kang capsules for the treatment of stroke and coronary artery disease; Jincishen Mixture used as an ancillary to treatment of cancer; Heiguteng capsules for the treatment of rheumatoid arthritis; Chongcao Qingfei capsules for the treatment of Chronic Obstructive Pulmonary Disease; Fengshi Gutong capsules for the treatment of rheumatoid arthritis; and Jingshu Granules for treatment of degenerative osteoarthritis. In addition, its product pipeline candidates comprise Jing Tong Ting, a phase III clinical trial product for menstrual pain; Da An Granules, a phase III ongoing product for anxiety; Yushuda Tablets, a phase III ongoing product for depression; and Dan Xian Kang Gu Capsules, a phase III design ongoing product for ischemic necrosis.

Simplexity Health (formerly Cell Tech International) hopes that the algae growing in the fountain of youth is the secret. More specifically, the company scrapes up Aphanizomenon flos-aquae, a type of blue-green algae, out of Upper Klamath Lake, and stirs it into nutritional supplements, body care products, and nutrition bars. Calling it Super Blue Green Algae, the company's product line includes digestive aids, weight loss supplements, antioxidants, and powdered drink mixes. Simplexity Health sells its products through a multi-level, direct marketing program using a network of independent associates.

Tetracore, Inc. company's FDA-approved Redline lab test can distinguish anthrax bacteria from similar microorganisms. Other bioterrorism countermeasures the firm offers include the BioThreat Alert testing kit used by first responders to detect various biological toxins including botulinum toxin (botulism) and staphylococcus aureus enterotoxin B (SEB). Tetracore also sells veterinary diagnostic (VetAlert) tests for foot-and-mouth disease, West Nile, and other diseases, and it markets antibodies (proteins) for use by research labs.

EraGen Biosciences, Inc. company is developing nucleic databases and other tools to help drug and diagnostics developers better use genomic information to streamline their R&D processes. Molecular clinical diagnostics, bioterrorism threat detection, and pesonalized medicine are other markets the company is pursuing. EraGen Biosciences has teamed with Luminex to distribute in vitro clinical diagnostics equipment that uses technology from both companies. Bayer HealthCare has licensed the company's MultiCode-PLx test for detecting cystic fibrosis.

Eurand, Inc. company, a subsidiary of Netherlands-based Eurand N.V., develops drug delivery technologies to help drugmakers improve the efficacy of their products. Eurand researches and manufactures drugs marketed in the Americas and Europe, mostly through partnerships with other pharma companies. Eurand's drug delivery systems include Biorise to make certain drugs water soluble; Diffucaps and Minitabs to control the release of drug components as they make their way through the digestive system; and AdvaTab and Liquitard to mask the taste of medicines. The company also conducts research for its parent's own portfolio of drugs under development.

Noven Pharmaceuticals, Inc. company develops drugs using its transdermal drug delivery system, which administers medication through a patch attached to the skin. Noven's patches include such female hormone replacement therapy products as Vivelle-Dot and CombiPatch, ADHD drug Daytrana (marketed by Shire), and a transmucosal lidocaine patch used for dental procedures. The company also produces and markets three psychiatric drugs. In 2009 Noven was acquired by Japanese drug-maker Hisamitsu Pharmaceutical for some $430 million.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.